The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody Imfinzi (durvalumab) with ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

Approval was based on improved survival outcomes vs platinum-based chemotherapy as demonstrated in the phase 3 NIAGARA study.

Neal Shore, MD, FACS, discussed findings from the SunRISe-4 trial of TAR-200 and cetrelimab in muscle-invasive bladder cancer ...

The promotional effort from Ferring features bladder cancer survivors sharing the news of a new treatment option.

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab) perioperative regimen has been approved by the US Food and Drug ...

Imfinzi was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings.

The FDA has approved Imfinzi (durvalumab) as neoadjuvant and adjuvant treatment in patients with muscle-invasive bladder cancer.

This study explores the relationship between gallstones, cholecystectomy, and cancer risk through both observational and ...

Coldwater Creek snakes through Wedgewood, hugging the subdivision’s contours on its meandering 14-mile journey northeast from ...

BOSTON & MONTREAL, April 01, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, ...